Survivorship: Cognitive Function, Version 1.2014

• DOI: 10.6004/jnccn.2014.0094
• Publication Date: 2017-04-14T12:05:30Z
• Authors: Crystal S. Denlinger; Jennifer A. Ligibel; Madhuri Are; K. Scott Baker; Wendy Demark-Wahn...; Debra L. Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H. Ku; Elizabeth Kvale; Terry S. Langbaum; Kristin Leonardi-...; Mary S. McCabe; Michelle Melisko; Jose G. Montoya; Kathi Mooney; Mary Ann Morgan; Javid J. Moslehi; Tracey O'Connor; Linda Overholser; Electra D. Paskett; Muhammad Raza; Karen L. Syrjala; Susan G. Urba; Mark T. Wakabayashi; Phyllis Zee; Nicole R. McMillian; Deborah A. Freedm...
• Keywords: Sleep Wake Disorders; Brain Neoplasms; Modafinil; Wakefulness-Promoting Agents; 3. Good health; Survival Rate; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Occupational Therapy; Adaptation, Psychological; Methylphenidate; Quality of Life; Psychological; Humans; Pain Management; Central Nervous System Stimulants; Adaptation; Benzhydryl Compounds; Cognition Disorders; Fatigue

Cognitive impairment is a common complaint among cancer survivors and may be consequence of the tumors themselves or direct effects cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over long term and, when more severe, can impact quality life function. This section NCCN Guidelines for Survivorship provides assessment, evaluation, management recommendations cognitive dysfunction in survivors. Nonpharmacologic interventions instruction coping strategies; distress, pain, sleep disturbances, fatigue; occupational therapy) are recommended, with pharmacologic as last line therapy whom other have been insufficient.